126 related articles for article (PubMed ID: 38372534)
1. [Not Available].
Medhioub M; Khsiba A; Mahmoudi M; Ben Mohamed A; Yakoubi M; Hamzaoui L
Tunis Med; 2023 Apr; 101(4):420-425. PubMed ID: 38372534
[TBL] [Abstract][Full Text] [Related]
2. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.
Flemming JA; Yang JD; Vittinghoff E; Kim WR; Terrault NA
Cancer; 2014 Nov; 120(22):3485-93. PubMed ID: 25042049
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.
Zhang H; Zhu J; Xi L; Xu C; Wu A
World J Surg Oncol; 2019 Apr; 17(1):75. PubMed ID: 31039803
[TBL] [Abstract][Full Text] [Related]
4. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract][Full Text] [Related]
5. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.
Ganne-Carrié N; Chastang C; Chapel F; Munz C; Pateron D; Sibony M; Dény P; Trinchet JC; Callard P; Guettier C; Beaugrand M
Hepatology; 1996 May; 23(5):1112-8. PubMed ID: 8621142
[TBL] [Abstract][Full Text] [Related]
6. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
7. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
[TBL] [Abstract][Full Text] [Related]
8. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.
Schöniger-Hekele M; Müller C; Kutilek M; Oesterreicher C; Ferenci P; Gangl A
Eur J Gastroenterol Hepatol; 2000 Aug; 12(8):941-8. PubMed ID: 10958223
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
[TBL] [Abstract][Full Text] [Related]
11. Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China.
Wang S; Liu B; Fan X; Gao Y; Hong M; Xu Y
Saudi J Gastroenterol; 2022; 28(5):362-368. PubMed ID: 35170433
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis.
Feng Z; Zhao H; Jiang Y; He Z; Sun X; Rong P; Wang W
Clin Nutr; 2020 Oct; 39(10):3132-3139. PubMed ID: 32057535
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of hepatocellular carcinoma in patients with cirrhosis: a comparative cohort study.
Kaze E; Henrion J
Acta Gastroenterol Belg; 2023; 86(3):412-416. PubMed ID: 37814557
[TBL] [Abstract][Full Text] [Related]
14. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis.
Wang JH; Chuah SK; Lu SN; Hung CH; Kuo CM; Tai WC; Chiou SS
Liver Int; 2014 Oct; 34(9):1340-8. PubMed ID: 24620731
[TBL] [Abstract][Full Text] [Related]
15. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
17. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
18. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
Audureau E; Carrat F; Layese R; Cagnot C; Asselah T; Guyader D; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Chazouillères O; Mallat A; Grangé JD; Attali P; d'Alteroche L; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Pol S; Nahon P;
J Hepatol; 2020 Dec; 73(6):1434-1445. PubMed ID: 32615276
[TBL] [Abstract][Full Text] [Related]
19. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
Wei J; Li H; Li C
J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis.
Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim DY
Scand J Gastroenterol; 2019 Oct; 54(10):1283-1290. PubMed ID: 31593481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
